CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Biocept Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Biocept Inc
9955 Mesa Rim Road
Phone: (858) 320-8200p:858 320-8200 SAN DIEGO, CA  92121  United States Ticker: BIOCQBIOCQ
Filed for Bankruptcy on 10/13/2023
Case #23-11731, filed in the U.S. Bankruptcy Court for the District of Delaware (Chapter 7)
Business Summary
Biocept, Inc. is a molecular oncology diagnostics company. The Company focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name CNSide. CNSide encompasses a suite of cellular and molecular technologies intended to aid medical professionals in CSF analysis and central nervous system (CNS) disease management in patients with solid tumors. It offers and conducts its commercialized diagnostic assays, which include cell capture and enumeration, immunocytochemistry, fluorescent in situ hybridization (FISH), and next generation sequencing (NGS). It has commercialized its CNSide assays for detecting and characterizing many different carcinomas and melanoma. These assays utilize its dual cellular and ctDNA technology platforms and provide biomarker analysis from a patient’s CSF sample.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022YesYesYes-Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8071 Medical laboratories
2835 In vitro and in vivo diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Bruce E.Gerhardt 72 7/13/2023 1/1/2010
Chief Operating Officer Philippe J.Marchand 59 3/8/2022 3/8/2022
Principal Accounting Officer, Vice President, Controller RobertWalsh 30 6/16/2023 8/1/2022
4 additional Officers and Directors records available in full report.

Business Names
Business Name
BIOC
BIOCQ

General Information
Number of Employees: 50 (As of 12/31/2022)
Outstanding Shares: 2,626,026 (As of 8/8/2023)
Shareholders: 11
Stock Exchange: OTC
Federal Tax Id: 800943522
Fax Number: (858) 320-8225


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 17, 2024